Apricus Biosciences to Present at the 24th Annual Piper Jaffray Healthcare Conference

Apricus Biosciences to Present at the 24th Annual Piper Jaffray Healthcare

SAN DIEGO, Nov. 21, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com) announced
today that Steve Martin, Interim Chief Executive Officer and Chief Financial
Officer, will present at the 24^th Annual Piper Jaffray Healthcare Conference,
being held at the New York Palace Hotel in New York City. Mr. Martin's
presentation will take place on Tuesday, November 27, 2012 at 4:30 p.m.
Eastern Time.

The presentation will be webcast and accessible to the public online at
http://www.media-server.com/m/p/m3w45839 or via the Company's website at
http://www.apricusbio.com. A replay will be available for 90 days after the

About Apricus Biosciences, Inc.

Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and
markets innovative treatments that help large patient populations across
numerous, high-demand therapeutic classes. The Company hasthree approved
products and has developed a strong pipeline of multiple late-stage product
candidates. With commercial operations in both the U.S. and Europe (France),
Apricus Bio generates revenues and growth from sales of its commercial
products and by out-licensing, in certain territories, its pipeline products
and NexACT^® technology.

Apricus Bio's growth strategy is to acquire, develop, and commercialize new
products through strategic partnerships. The Company currently has commercial
partnerships with multiple large pharmaceutical companies including Novartis,
Takeda, Abbott Laboratories, Sandoz, Warner Chilcott, and Bracco, and
co-promotes multiple products in France.

Apricus Bio is headquartered in San Diego, CA and is publicly traded on the
NASDAQ Capital Market under the ticker symbol APRI.

For further information on Apricus Bio, visit http://www.apricusbio.com, and
for information on its subsidiary please visit http://www.nexmedusa.com. You
can also receive information at http://twitter.com/apricusbio.

CONTACT: Apricus Bio Investor Relations:
         David Pitts
         Argot Partners

Apricus logo
Press spacebar to pause and continue. Press esc to stop.